New hope for CLL patients: consolidation therapy aims for deeper remission
NCT ID NCT07108998
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tests whether adding the drug epcoritamab after standard treatment can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. About 22 adults who have already received at least 12 months of a BTK inhibitor (acalabrutinib or zanubrutinib) with or without obinutuzumab will receive epcoritamab for 12 cycles. The main goal is to see if this approach can make cancer cells undetectable in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.